1 Guo Y, Hao Y, Guan G, Ma S, Zhu Z, Guo F et al. Mukonal Inhibits Cell Proliferation, Alters Mitochondrial Membrane Potential and Induces Apoptosis and Autophagy in Human CNE1 Nasopharyngeal Carcinoma Cells. Med. Sci. Monitor25, 1976-1983 (2019).
2 Wei K-R, Zheng R-S, Zhang S-W, Liang Z-H, Li Z-M, Chen W-Q. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin. J. Cancer36 (2017).
3 Wu F, Wang R, Lu H, Wei B, Feng G, Li G et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Treatment outcomes of a prospective, multicentric clinical study. Radiother. Oncol. 112, 106-111 (2014).
4 Ak S, Kilic C, Ozlugedik S. Correlation of PET-CT, MRI and histopathology findings in the follow-up of patients with nasopharyngeal cancer. Brazil. J. Otorhinolaryngol. (2020).
5 Wong EHC, Liew YT, Abu Bakar MZ, Lim EYL, Prepageran N. A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma. Eur. Arch. Oto-Rhino-L.274, 275-281 (2017).
6 Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Research7 (2018).
7 Ni X, Song Q, Cassady K, Deng R, Jin H, Zhang M et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8(+) T cells. J. Clin. Invest.127, 1960-1977 (2017).
8 Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L et al. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. Clin. Cancer Res.24, 5574-5584 (2018).
9 Lee HM, Okuda KS, Gonzalez FE, Patel V. Current Perspectives on Nasopharyngeal Carcinoma. In: Rhim JS, Dritschilo A, Kremer R (eds). Human Cell Transformation: Advances in Cell Models for the Study of Cancer and Aging. pp 11-34 (2019).
10 Lee AWM, Ma BBY, Ng WT, Chan ATC. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. J. Clin. Oncol.33, 3356-+ (2015).
11 Xu T, Tang J, Gu M, Liu L, Wei W, Yang H. Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge. Curr. Oncol.20, E406-E419 (2013).
12 Parzych KR, Klionsky DJ. An Overview of Autophagy: Morphology, Mechanism, and Regulation. Antioxid. Redox Sign. 20, 460-473 (2014).
13 Chen K-H, Guo Y, Li L, Qu S, Zhao W, Lu Q-T et al. Cancer stem cell-like characteristics and telomerase activity of the nasopharyngeal carcinoma radioresistant cell line CNE-2R. Cancer Med. 7, 4755-4764 (2018).
14 Zhao Y-y, Tian Y, Liu L, Zhan J-h, Hou X, Chen X et al. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma. Drug Des. Dev. Ther.12, 2655-2663 (2018).
15 Zheng R, Chen K, Zhang Y, Huang J, Shi F, Wu G et al. Apogossypolone induces apoptosis and autophagy in nasopharyngeal carcinoma cells in an in vitro and in vivo study. Oncol. Lett.14, 751-757 (2017).
16 Han Y, Shi D, Li J. Inhibition of Nasopharyngeal Carcinoma by Beta-Lapachone Occurs by Targeting the Mammalian Target of Rapamycin (mTOR)/PI3K/AKT Pathway, Reactive Oxygen Species (ROS) Production, and Autophagy Induction. Med. Sci. Monitor 25, 8995-9002 (2019).
17 Xiao-Fen L, Cong-Xiang S, WEN-zhong. Expression and effective analysis of telomerase inhibitor PinX1 in nasopharyngeal carcinoma cells. Chin. J. Otorhinolaryngol. Skull Base Surg.17, 161-166 (2011).
18 Khan T, Relitti N, Brindisi M, Magnano S, Zisterer D, Gemma S et al. Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas. Med. Res. Rev.40, 1002-1060 (2020).
19 Yu C, Chen F, Wang X, Cai Z, Yang M, Zhong Q et al. Pin2 telomeric repeat factor 1-interacting telomerase inhibitor 1 (PinX1) inhibits nasopharyngeal cancer cell stemness: implication for cancer progression and therapeutic targeting. J. Exp. Clin. Cancer Res.39 (2020).
20 Liang H, Xiong Z, Li Y, Kong W, Yao Z, Li R et al. Prognostic and Clinicopathological Value of PINX1 in Various Human Tumors: A Meta-Analysis. Biomed Res. Int. 2018 (2018).
21 Zuo J, Wang D-H, Zhang Y-J, Liu L, Liu F-L, Liu W. Expression and mechanism of PinX1 and telomerase activity in the carcinogenesis of esophageal epithelial cells. Oncol. Rep.30, 1823-1831 (2013).
22 Fan X-K, Yan R-H, Geng X-Q, Li J-S, Chen X-M, Li J-Z. Biological significance of PinX1 telomerase inhibitor in esophageal carcinoma treatment. Exp. Ther. Med.12, 2196-2200 (2016).
23 Shen C, Chen F, Wang H, Li G, Yu C, Wang X et al. The Pinx1 Gene Downregulates Telomerase and Inhibits Proliferation of CD133(+) Cancer Stem Cells Isolated from a Nasopharyngeal Carcinoma Cell Line by Regulating Trfs and Mad1/C-Myc/p53 Pathways. Cell. Physiol. Biochem.49, 282-294 (2018).
24 Bishop E, Bradshaw TD. Autophagy modulation: a prudent approach in cancer treatment? Cancer Chemoth. Pharm.82, 913-922 (2018).
25 Amaravadi R, Kimmelman AC, White E. Recent insights into the function of autophagy in cancer. Genes Dev.30, 1913-1930 (2016).
26 Brech A, Ahlquist T, Lothe RA, Stenmark H. Autophagy in tumour suppression and promotion. Mol. Oncol.3, 366-375 (2009).
27 Zhu J-F, Huang W, Yi H-M, Xiao T, Li J-Y, Feng J et al. Annexin A1-suppressed autophagy promotes nasopharyngeal carcinoma cell invasion and metastasis by PI3K/AKT signaling activation. Cell Death Dis.9 (2018).
28 Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell. Signal.26, 2694-2701 (2014).
29 Fan C, Tang X, Ye M, Zhu G, Dai Y, Yao Z et al. Qi-Li-Qiang-Xin Alleviates Isoproterenol-Induced Myocardial Injury by Inhibiting Excessive Autophagy via Activating AKT/mTOR Pathway. Front. Pharmacol.10 (2019).
30 Murugan AK. mTOR: Role in cancer, metastasis and drug resistance. Semin. Cancer Biol.59, 92-111 (2019).
31 Wang W, Wen Q, Xu L, Xie G, Li J, Luo J et al. Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma. Plos One9 (2014).
32 Lin Y-T, Wang H-C, Hsu Y-C, Cho C-L, Yang M-Y, Chien C-Y. Capsaicin Induces Autophagy and Apoptosis in Human Nasopharyngeal Carcinoma Cells by Downregulating the PI3K/AKT/mTOR Pathway. Int. J. Mol. Sci.18 (2017).
33 Karin M. Nuclear factor-kappa B in cancer development and progression. Nature441, 431-436 (2006).